menu
    • menu
    [{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"Recordati Rare Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mechlorethamine","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Centre for Human Drug Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Centre for Human Drug Research \/ Recordati Rare Diseases","highestDevelopmentStatusID":"1","companyTruncated":"Centre for Human Drug Research \/ Recordati Rare Diseases"},{"orgOrder":0,"company":"Juniper Biologics","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Mechlorethamine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Juniper Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Juniper Biologics \/ Helsinn Advanced Synthesis","highestDevelopmentStatusID":"15","companyTruncated":"Juniper Biologics \/ Helsinn Advanced Synthesis"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mechlorethamine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mechlorethamine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Helsinn Advanced Synthesis \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Undisclosed"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Mechlorethamine","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Kyowa Kirin"},{"orgOrder":0,"company":"Rochester Skin Lymphoma Medical Group","sponsor":"Rochester General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Mechlorethamine","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Rochester Skin Lymphoma Medical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Rochester Skin Lymphoma Medical Group \/ Rochester General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Rochester Skin Lymphoma Medical Group \/ Rochester General Hospital"},{"orgOrder":0,"company":"Thomas Jefferson University","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Mechlorethamine","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thomas Jefferson University \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Thomas Jefferson University \/ Johnson & Johnson"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Mechlorethamine","moa":"DNA","graph1":"Dermatology","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Mayo Clinic \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Johnson & Johnson"},{"orgOrder":0,"company":"Sidney Kimmel Cancer Center, Thomas Jefferson University","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Mechlorethamine","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Sidney Kimmel Cancer Center, Thomas Jefferson University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Sidney Kimmel Cancer Center, Thomas Jefferson University \/ Johnson & Johnson"}]

    Find Clinical Drug Pipeline Developments & Deals for Mechlorethamine

    Menu

    Mechlorethamine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Helsinn Publishes New Data Evaluating Chlormethine Gel’s Mode Of Action In Dermatology And Therapy

                            Details : VALCHLOR® (mechlorethamine) gel 0.016% is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy.

                            Product Name : Ledaga

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 18, 2022

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Helsinn Presents Novel Data On Chlormethine Gel At EORTC Cutaneous Lymphomas Tumors Group Annual Meeting

                            Details : LEDAGA® (chlormethine) gel is an alkylating drug indicated for the topical treatment of MF-CTCL in adult patients. LEDAGA® is a gel which is applied topically once a day.

                            Product Name : Ledaga

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 21, 2022

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Juniper Biologics

                            Singapore arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Juniper Biologics

                            Singapore arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Helsinn Advanced Synthesis

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Helsinn Healthcare SA Signs Exclusive License Agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlorme...

                            Details : Under the agreement, the registeration, distribution, promotion, market and sell LEDAGA® (chlormethine gel) in Australia, Asia and the Middle East* as a topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (“MF-CTCL”) in adults.

                            Product Name : Ledaga

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 01, 2022

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Helsinn Advanced Synthesis

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Centre for Human Drug Research

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Centre for Human Drug Research

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Recordati Rare Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides

                            Details : Chlormethine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Mycosis Fungoides.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 31, 2022

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Recordati Rare Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Kyowa Kirin

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Helsinn and Kyowa Kirin Sign License Agreement to Strengthen Their Presence in Asia Pacific’s Rare Disease T...

                            Details : Helsinn will grant Kyowa Kirin an exclusive license to distribute, promote, market, and sell VALCHLOR® in China. Helsinn will be responsible for clinical development, regulatory activities, and the supply of VALCHLOR® for commercial use in China.

                            Product Name : Ledaga

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 01, 2020

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Kyowa Kirin

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Mayo Clinic

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Mayo Clinic

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Johnson & Johnson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Valchlor in the Treatment of Lichen Planopilaris

                            Details : Mechlorethamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lichen Planus.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 31, 2018

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Johnson & Johnson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Rochester Skin Lymphoma Medical Group

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Rochester Skin Lymphoma Medical Group

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Rochester General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mechlorethamine Induced Contact Dermatitis Avoidance Study

                            Details : Mechlorethamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma, T-Cell, Cutaneous.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 20, 2017

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Rochester General Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sidney Kimmel Cancer Center, Thomas Jefferson University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sidney Kimmel Cancer Center, Thomas Jefferson University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Johnson & Johnson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients...

                            Details : Mechlorethamine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Mycosis Fungoides.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 20, 2017

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Johnson & Johnson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Thomas Jefferson University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Thomas Jefferson University

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Johnson & Johnson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis...

                            Details : Mechlorethamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Mycosis Fungoides.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 29, 2016

                            Lead Product(s) : Mechlorethamine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Johnson & Johnson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth